@article{5feb95ccb9de4423aff4134446b6a237,
title = "Covid-19 pandemic and cancer clinical trial pandemonium: Finding the silver lining",
keywords = "COVID19, Cancer, Clinical trials, Mortality, Registry",
author = "Aakash Desai and Vivek Subbiah",
note = "Funding Information: Conflict of Interest: Vivek Subbiah disclosed research funding/grant support for clinical trials from FUJIFILM Pharmaceuticals USA, Inc., Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-Sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Loxo Oncology, Medimmune, Altum, Dragonfly Therapeutics, Takeda and Roche/Genentech, National Comprehensive Cancer Network, NCI-CTEP. Supported by UT MD Anderson Cancer Center (P30 CA016672). Travel assistance was provided by Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte, US-FDA. Vivek Subbiah disclosed a consultancy advisory role for Helsinn, LOXO Oncology/Eli Lilly, Daichi Sankyo, R-Pharma US, INCYTE, Medimmune, Novartis. Aakash Desai has nothing to disclose.",
year = "2021",
doi = "10.36401/JIPO-20-X7",
language = "English (US)",
volume = "4",
pages = "64--66",
journal = "Journal of Immunotherapy and Precision Oncology",
issn = "2666-2345",
publisher = "Innovative Healthcare Institute",
number = "2",
}